New drug CS231295 enters first human trial for tough cancers

NCT ID NCT07612488

Not yet recruiting Disease control Sponsor: ThalassaX Therapeutics United States Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find the right dose, and see early signs of whether the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS231295 (a targeted drug that blocks proteins involved in tumor growth and blood vessel formation)
What this could lead to: If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that no longer respond to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 42 people, focused mainly on safety and dosing. It is too soon to know if the drug will work, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCE SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCE SOLID TUMORS ADVANCED MALIGNANT SOLID TUMORS

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.